And in tonight's future of everything, we turn to the land down under where a tech entrepreneur has done what any of us wish we could do if our dog got cancer. He used AI to beat that cancer by creating a treatment genetically made to save his best mate, Rosie. This is Paul Cunningham we're talking about.And when he was told that Rosie only had a few months left to live, he turned to ChachiPT. Uh and then with the help of some scientists at the University of New South Wales, he analyzed the healthy DNA sequ ...

AMERICA'S future as a science leader may depend on students like the ones you're going to meet tonight. Teenagers from Lambert High School in suburban Atlanta. They may have just found a better way to detect and treat Lyme disease, which affects nearly a half million Americans annually. Their primary tool, the revolutionary gene editing technique known as Crisper. And these Crisper kids did it to try to prove they are the best in the world, competing at a kind of science Olympics in Paris called Gem, short ...

Welcome everyone. Welcome to GTC. My name is Jason Fenwick.Uh I'm on the genomics and healthcare team here at NVIDIA. And today I'll be the the host for the session. Our speaker for today is Yurgi Camlong.He is pioneering the global datadriven medicine movement. Founded co-founded Sophia Genetics in 2011. is a member of the advisory council on digital transformation for for the Swiss government and was recognized by EY as emergent entrepreneur of the year.A molecular biologist with a PhD and EMBA. He has be ...

Illumina said the Chinese government has lifted a ban on the company selling its DNA sequencing machines inside the country https://t.co/XyQQuUvrYC ...

Core Insights - Illumina Inc. reported better-than-expected third-quarter earnings, with adjusted earnings of $1.34 per share, surpassing the consensus estimate of $1.17 [2] - The company's revenue reached $1.084 billion, exceeding the consensus of $1.065 billion, remaining flat year-over-year on both reported and constant currency basis [3][4] Financial Performance - The performance reflects momentum in clinical markets, with sequencing consumables revenue growing at a high single-digit rate year-over-year [2] - Operating cash flow for the third quarter was $284 million, down from $316 million last year, while free cash flow was $253 million, compared to $284 million previously [5] Guidance and Future Outlook - Illumina raised its fiscal 2025 earnings guidance from $4.45-$4.55 per share to $4.65-$4.75 per share, against a consensus of $4.50 [6] - The company expects a constant currency revenue decline between -1.5% and -0.5%, improved from the previous range of -2.5% to -1.5% [6] - Revenue growth outside of China is anticipated to be between 0.5% and 1.5% on a constant currency basis, with no change from prior guidance at the midpoint [6] Market Reaction - Illumina shares were up 21.45% at $120.24 following the earnings report, indicating strong market confidence [7]

Core Insights - Illumina reported Q3 2025 financial results that exceeded guidance for revenue and earnings, driven by growth in the clinical segment, marking a return to growth outside of China [2][9]. Financial Performance - Revenue for Q3 2025 was $1,084 million, flat compared to Q3 2024 [9]. - GAAP operating margin was 21.0%, while non-GAAP operating margin was 24.5% for Q3 2025 [9][22]. - GAAP diluted EPS was $0.98, and non-GAAP diluted EPS was $1.34 for Q3 2025 [9][22]. - Net income for Q3 2025 was $150 million, down from $642 million in Q3 2024 [9][24]. Cash Flow and Expenditures - Cash flow from operations was $284 million, compared to $316 million in the prior year [3][20]. - Free cash flow for Q3 2025 was $253 million, down from $284 million in the prior year [3][20]. - Capital expenditures for the quarter were $31 million [3]. Guidance and Outlook - The company expects a total revenue decline in the range of (1.5%) to (0.5%) for fiscal year 2025, an improvement from the previous range of (2.5%) to (1.5%) [9]. - Revenue growth outside of China is projected to be between 0.5% and 1.5% on a constant currency basis [9]. - Non-GAAP operating margin guidance has been raised to a range of 22.75% to 23% [9]. Recent Developments - Illumina launched several new products and initiatives, including a 5-base solution for genomic insights and BioInsight for technology-driven discovery [10]. - The company expanded its personalized cancer care efforts through new pharmaceutical partnerships [10].

Core Business & Strategy - Basecamp Research aims to digitize nature and unlock solutions evolved in biodiversity for humanity's benefit [5] - The company is building a bridge between biotechnology and biodiversity, addressing the data wall in biology [6][7] - Basecamp Research positions itself as a data company, utilizing AI models to interrogate and represent biological data [9] - The company's mission is to map global biodiversity, rivaling the Human Genome Project in scientific advancement [32][33] - Basecamp Research is scaling its database by 10x annually, presenting a significant engineering challenge [21] Data & Technology - The company converts biological material into data, processing hundreds of millions of CPU hours with billions of annotations [4][2] - Basecamp Research's data asset aims to represent the diversity in nature, enabling scaling laws in biology and transforming biotechnology [9] - The company collaborates with Microsoft and NVIDIA to scale models on large compute systems, combining data and model scaling expertise [14][26][28] - Basecamp Research leverages Azure and NVIDIA BioNeMo to optimize architectures for its unique data, training foundation models [25][26][27] Biodiversity & Impact - Costa Rica, covering 0.03% of Earth's surface, holds approximately 6% of the world's biodiversity, making it a key location for data collection [3] - Basecamp Research enhances capacity in bioeconomy locations by building labs, sharing data, and training scientists [37] - The company aims to pass revenue back to partner countries, demonstrating the value of biodiversity data [38]

AI Model Introduction - Google DeepMind introduces AlphaGenome, a new DNA sequence model accessible via API [1] - AlphaGenome aims to help scientists understand DNA, the instruction manual for life [1] Potential Applications - The model can quickly predict the impact of genetic changes, aiding in generating new hypotheses and driving biological discoveries [1] - AlphaGenome's predictions can be used to understand genome function and develop new treatments [1]